Antiviral Research

Interfering with HIV-1 Replication by Affecting Cellular Factors. HIV-1 Inhibition by Hydroxyurea.
pp. 225-225(1)
Authors: Lori F.; Cara A.; Malykh A.G.; Sun D.; Lisziewicz J.; Weinstein J.; Gallo R.C.

Phosphorylation of HIV-1 Matrix Protein is Necessary for Nuclear Targeting of Viral Preintegration Complex.
pp. 226-226(1)
Authors: Bukrinskaya A.G.; Ghorpade A.; Ragland A.M.; Heinzinger N.K.; Smithgall T.E.; Lewis R.E.; Stevenson M.

Phosphonate Derivatives of Six Membered-ring Nucleosides: Synthesis and Antiviral Evaluation.
pp. 226-226(1)
Authors: Perez-Perez M.J.; Balzarini J.; Rozenski J.; De Clercq E.; Herdewijn P.

Mode of Action of SDZ NIM 811, a Non-Immunosuppressive Cyclosporin A Analog with Activity against Human Immunodeficiency Virus Type 1 (HIV-1)
pp. 227-227(1)
Authors: Rosenwirth B.; Billich A.; Steinkasserer A.; Hammerschmid F.; Peichl P.

Cyclosporin A Modulation of Primary Simian Immunodeficiency virus (SIV) Infection in Rhesus Monkeys.
pp. 227-227(1)
Authors: Martin L.N.; Murphey-Corb M.; Mack P.; Baskin G.B.; Pantaleo G.; Vaccarezza M.; Fox C.H.; Fauci A.S.

Ingenol Derivatives, Ingredient of 'Kansui', are Highly Potent Inhibitor of HIV
pp. 228-228(1)
Authors: Fujiwara M.; Ijichi K.; Konno K.; Yokota T.; Tokuhisa K.; Katsuura K.; Uemura D.; Shigeta S.; Baba M.

1592U89 Succinate - A Potent, Selective Anti-HIV Carbocyclic Nucleoside.
pp. 228-228(1)
Authors: Daluge S.M.; Good S.S.; Faletto M.B.; Martin M.T.; Miller W.H.; Averett D.R.; St. Clair M.H.; Boone L.R.; Tisdale M.; Reardon J.E.

1592U89 Succinate - Preclinical Toxicological and Disposition Studies and Preliminary Clinical Pharmacokinetics.
pp. 229-229(1)
Authors: Good S.S.; Daluge S.M.; Ching S.V.; Ayers K.M.; Mahony W.B.; Faletto M.B.; Domin B.A.; Owens B.S.; Dornsife R.E.; McDowell J.A.; LaFon S.W.; Symonds W.T.

A randomized, double-blind, placebo-controlled phase I/II evaluation of 9-[2-(bispivaloyloxy-methyl) phosphonyl-methoxy]adenine (bis-POM PMEA), an orally bioavailable prodrug of the anti-HIV nucleotide
pp. 229-229(1)
Authors: Barditch-Crovo P.P.; Toole J.; Burgee H.; Wachsman M.; Ebeling D.; Cundy K.; Jaffe H.; Lietman P.

A Potent Peptidomimetic Inhibitor of HSV Ribonucleotide Reductase with Antiviral Activity in vivo.
pp. 230-230(1)
Authors: Deziel R.; Moss N.; Liuzzi M.; Beaulieu P.; Bonneau A.-M.; Bousquet C.; Llinas-Brunet M.; Chafouleas J.G.; Duceppe J.-S.; Ferland J.-M.; Garneau M.; Gauthier J.; Ghiro E.; Goulet S.; Grenier L.; Jaramillo J.; Krogsrud R.L.; Lagace L.; McCollum R.; Nawoot S.; Plante R.; Wernic D.; Guindon Y.

Resistance of HSV-1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.
pp. 231-231(1)
Authors: Bonneau A.M.; Kibler P.; White P.; Bousquet C.; Dansereau N.; Cordingley M.

Antiviral activity of 2-phosphonomethoxyalkyl derivatives of N6-substituted 6-aminopurines
pp. 231-231(1)
Authors: Holy A.; Snoeck R.; Andrei G.; Balzarini J.; De Clercq E.

Ultratrace Determination of Penciclovir-triphosphate (PCV-TP) in a Herpes Simplex Virus Type 1 (HSV-1)-Infected Cell Line using Flow-Injection Electrospray Ionization Tandem Mass Spectrometry (MS-MS).
pp. 232-232(1)
Authors: Smyrnis E.M.; Burton R.; Abbott F.; Wall R.A.; Sacks S.L.

Famciclovir and valaciclovir treatment during acute HSV-1 infection of mice have markedly different effects on subsequent virus reactivation from ganglia.
pp. 232-232(1)
Authors: Field H.; Thackray A.

Adjuvant effect of imiquimod when combined with HSV glycoprotein vaccine in guinea pigs with recurrent HSV-2 genital herpes.
pp. 233-233(1)
Authors: Harrison C.J.; Miller R.L.; Bernstein D.I.

DNA Vaccine Protects Mice from Vaginitis and Death due to Herpes Simplex Virus Type 2 (HSV-2).
pp. 233-233(1)
Authors: Kriesel J.; Ricigliano J.; Spruance S.; Araneo B.

Valtrex^* (Valaciclovir, VACV) for the Treatment of Recurrent Genital Herpes.
pp. 234-234(1)
Authors: International Valaciclovir HSV Study Group; Safrin S.

New Classes of Reagents that Attack Conserved and Chemically Reactive Zinc Fingers in Retroviral Nucleocapsid Proteins: A strategy for Rational Drug Design
pp. 235-235(1)
Authors: Rice W.G.; Schaeffer C.A.; Turpin J.A.; Coren L.; Sowder R.C.; Kane B.; Bader J.; Arthur L.O.; Henderson L.E.

Anti-HIV activities of new PETT compounds in cell cultures
pp. 236-236(1)
Authors: Oberg B.; ahgren C.; Classon B.; Engelhardt P.; Hogberg M.; Johansson N.-G.; Kangasmetsa J.; Lind P.; Lopez C.; Mauldin S.; Morin J.M.; Munroe J.; Noreen R.; Rydergard C.; Sahlberg C.; Ternansky R.J.; Vrang L.

Novel Mutations in the Reverse Transcriptase of HIV-1 Reduce Susceptibility to Phosphonoformate in Laboratory and Clinical Isolates
pp. 236-236(1)
Authors: Mellors J.; Bazmi H.; Schinazi R.; Roy B.; Hsiov Y.; Arnold E.; Weir J.; Mayers D.

Thiocarboxanilide Derivatives Synergistically Suppress the Breakthrough of Human Immunodeficiency Virus Type 1 (HIV-1) in CEM Cell Cultures When Used in Combination with TSAO Derivatives
pp. 237-237(1)
Authors: Balzarini J.; Perez-Perez M.-J.; Velazquez S.; San-Felix A.; Camarasa M.-J.; De Clercq E.; Karlsson A.

DMP450, A New Cyclic Urea Inhibitor of HIV Protease With Potent In Vitro Antiviral Activity
pp. 237-237(1)
Authors: Winslow D.L.; Reid C.D.; Garber S.; Aldrich P.; Scarnati H.; Anton E.; Otto M.J.

In Vivo Selection by Monotherapy of HIV-1 Variants Resistant to Multiple Protease Inhibitors.
pp. 238-238(1)
Authors: Condra J.H.; Schleif W.A.; Blahy O.M.; Gabryelski L.J.; Graham D.J.; Quintero J.C.; Rhodes A.; Robbins H.L.; Roth E.; Shivaprakash M.; Titus D.L.; Yang T.; Emini E.A.; Teppler H.; Squires K.E.; Deutsch P.J.

Antiviral Agents Reduce Viral Load and Delay the Detection of Infected Cells In Vivo in the HIV-Infected Hu-PBMC SCID Mouse Model. M
pp. 238-238(1)
Authors: Ussery M.A.; Broud D.D.; Wood O.L.; Kunder S.C.; Black P.L.; Dailey P.J.; Wilber J.C.; Yang L.; Piatek M.; Lifson J.D.

Nucleoside Anti-HIV Efficacy in the Xenotransplanted Nude Mouse Model.
pp. 239-239(1)
Authors: Welsh B.M.; Belzer S.W.; Wetherall N.T.

Multiple Drug Effect Analyses with Confidence Intervals for the Evaluation of Interactions of Combined Antiviral Agents Against Hepatitis B Virus.
pp. 240-240(1)
Authors: Schinazi R.F.; Korba B.E.; Belen'kii M.; Chu C.K.; Gangemi J.D.

Cellular Pharmacology of - L - Dideoxycytidine, - L - 2', 3' Dideoxy - 5 - Fluorocytidine, and - D - 2', 3' Dideoxy - 5 - Fluorocytidine.
pp. 241-241(1)
Authors: Martin L.T.; Schinazi R.F.; Gosselin G.; Imbach J.-L.; Sommadossi J.-P.

Selective Liver Targeting of a Derivatized Antiviral Nucleoside Analogue by Recombinant Chylomicrons.
pp. 241-241(1)
Authors: Rensen P.C.N.; van Dijk M.C.M.; Havenaar E.C.; Bijsterbosch M.K.; Kruijt J.K.; van Berkel T.J.C.

Penciclovir: A Novel Nucleoside Analogue with Potent Activity against Duck Hepatitis B Virus in vivo.
pp. 242-242(1)
Authors: Locarnini S.; Lin E.; Luscombe C.; Edwards P.; Anderson D.; Shaw T.

Inhibition of HPV-11 Gene Expression with Chimeric Methylphosphonate Oligomers
pp. 242-242(1)
Authors: Giachetti C.; Marich J.; Salunga R.; Jaeger J.; Tseng B.; Selling B.

SV40 DNA Hybridization Assay: Use as a Primary Cell-Based Screen For Antiviral Inhibitors of Human Papovaviruses
pp. 243-243(1)
Authors: Barnes J.A.; Phelps W.C.

The SCID-Ra Model For Evaluation Of Inhibitors Of Papillomaviruses.
pp. 243-243(1)
Authors: Lobe D.C.; Dunn C.S.; Phelps W.C.

Multi-center Safety and Efficacy Trial Evaluating Three Times per Week Application of 1% and 5% Topical Imiquimod for the Treatment of Genital/Perianal Warts.
pp. 244-244(1)
Authors: Topical Imiquimod HPV Study Group; Edwards L.; Ferenczy A.; Eron L.; Baker D.; Fox T.; Gayoso K.; Hougham A.; Owens M.

Inhibition of HIV- and HBV-Virus Replication by 2,6-Disubstituted Purine 2', 3'-Dideoxynucleosides.
pp. 245-245(1)
Authors: Koszalka G.W.; Burns C.L.; St. Clair M.; Frick L.; Lambe C.U.; Paff M.T.; Nelson D.J.; Korba B.; Ayers K.; Krenitsky T.A.

Stereospecific Synthesis and Antiviral Evaluation of Purine Nucleoside L-Enantiomers: -L-Ara-A, 3'-Deoxy--L-Ribo-A and -L-Lyxo-A
pp. 246-246(1)
Authors: Imbach J.-L.; Boudou V.; Bergogne M.-C.; Gosselin G.

The Synthesis and Biological Evaluation of Phosphate Triester Alkyl Lysophospholipids (ALPs) as Potential Antineoplastic and Anti-HIV Agents
pp. 246-246(1)
Authors: Wang Y.; McGuigan C.; Hay A.; Mahmood N.; Balzarini J.; De Clercq E.; Riley P.

Enzymatic Synthesis of 3'-Azido-3'-Deoxy-5'-O-(1,2-Dihexadecanoyl-3-sn-Phosphatidyl)thymidine Involving Commercially Available Phospholipase D Type VII.
pp. 247-247(1)
Authors: Reitter B.E.; Rideout J.L.; Almond M.R.

5-Halo-6-alkoxy(or azido)-5,6-dihydro-3'-azido-3'-deoxythymidine Diastereomers as Potential Prodrugs of 3'-Azido-3'-deoxythymidine (AZT).
pp. 247-247(1)
Authors: Knaus E.E.; Wiebe L.I.; Wang L.; Kumar R.; Morin K.W.; Todd K.G.; Baker G.B.

Chemoenzymatic Synthesis of Carbocyclic Nucleotide Mimics Possessing Potent Activity Against HIV-Reverse Transcriptase
pp. 248-248(1)
Authors: Clements C.J.; Roberts S.M.; Merlo V.

A New Synthesis of 2'-Deoxypyrimidine Nucleosides Involving Sodium Cyanoborohydride.
pp. 248-248(1)
Authors: Almond M.R.; Reitter B.E.; Rideout J.L.

4(S)(6-Amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol: Synthesis, Enzymology and Anti-HIV Studies
pp. 249-249(1)
Authors: Nair V.; Rideout J.L.; St. Clair M.H.; Krasny H.C.; Reardon J.E.; Dornsife R.; Spector T.

Structure-Activity Relationships Studies in TSAO-T derivatives modified at the 2'-and 5'-positions of the sugar moiety
pp. 249-249(1)
Authors: Ingate S.T.; Camarasa M.J.; De Clercq E.; Balzarini J.

The Synthesis of Novel Phospholipids with Potential Antineoplastic and Antiviral Activity.
pp. 250-250(1)
Authors: Wilson M.; McGuigan C.; Hay A.; Mahmood N.; Balzarini J.; De Clercq E.; Postle A.; Riley P.

On the Bioisosteric Potential of the Pyridazine Core in the Systematic Structural Modification of Antiviral Agents
pp. 250-250(1)
Authors: Heinisch G.; Easmon J.; Matuszczak B.

Preparation and Anti-Viral Activity of Oligoribonucleotides Containing 5-Fluorouridine
pp. 251-251(1)
Authors: Gmeiner W.H.; Sahasrabudhe P.; Schulte N.; Iversen P.L.; Rhode S.

Preparation of Enantiomerically Pure Branched DNA for Shape Specific Binding of RNA Hairpin Loops
pp. 251-251(1)
Authors: Gmeiner W.H.; Zhong Y.; Pon R.T.

Development of a Non-Hazardous Biological Assay System for the Screening of Anti-HIV Compounds.
pp. 252-252(1)
Authors: Kiser R.; Makovsky S.T.; Bader J.P.; Lyerly H.K.; Cullen B.R.; Clanton D.J.

Fluorometric Measurement of Reverse Transcriptase Activity with 4',6-diamidino-2-phenylindole (DAPI).
pp. 252-252(1)
Authors: Chavan S.; Prochaska H.

Heat Shock Induces HIV-1 Replication in Chronically Infected Promyelocyte Cell Line OM10.1: Implication of a New Anti- HIV-1 Assay In Vitro.
pp. 253-253(1)
Authors: Hashimoto K.; Baba M.; Gohnai K.; Sato M.; Shigeta S.

High Throughput Screening for Small Molecule Inhibitors of the HIV Rev-RRE Interaction.
pp. 253-253(1)
Authors: Arenas J.E.; Lam K.T.; Lillie J.

Thiadiazole Derivatives as Highly Potent Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1)
pp. 254-254(1)
Authors: Fujiwara M.; Ijichi K.; Konno K.; Yokota T.; Hanasaki Y.; Watanabe H.; Katsuura K.; Shirakawa S.; Takayama H.; Sakai S.; Shigeta S.; Baba M.

QSAR Study of Nucleoside Analogs with Anti-HIV Activity Using Molecular Similarity Analysis and Structure-Activity Maps
pp. 254-254(1)
Authors: Tsai C.C.; Durand P.J.; Taylor K.J.; Baker J.W.

Intracellular activation and cytotoxicity of combinations of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
pp. 255-255(1)
Authors: Palmer S.; Cox S.

Activity of AZT and ddI When Used in Combination With Other Mechanistically Diverse Inhibitors of HIV Replication.
pp. 255-255(1)
Authors: Buckheit R.W.; Russell J.D.

Use of Drug Combinations for Selection of Human Immunodeficiency Virus Type 1 (HIV-1) Variants with Decreased Sensitivity to Hydroxyethylurea Isostere Containing Protease Inhibitors in vitro.
pp. 256-256(1)
Authors: Smidt M.L.; Potts K.E.; Tucker S.P.; Stiebel T.R.; Stallings W.C.; Clare M.; Bryant M.L.

Combined antiviral effect of flavonoid and acyclovir
pp. 256-256(1)
Authors: Beladi I.; Mucsi I.; Veckenstedt A.; Pusztai R.; Gyulai Z.

[AZT]-[TSAO-T] And [AZT]-[HEPT] Heterodimers as Potential Bi-Functional Inhibitors of HIV-1 Reverse Transcriptase. Synthesis, Structural Assignment and Anti-HIV Activity
pp. 257-257(1)
Authors: Camarasa M.J.; Velazquez S.; Alvarez R.; San-Felix A.; Jimeno M.L.; De Clercq E.; Balzarini J.

Optimization of antiviral and kinetic properties of PETT compounds, a class of potent non-nucleoside HIV-RT inhibitors.
pp. 257-257(1)
Authors: Johansson N.-G.; Classon B.; Engelhardt P.; Hogberg M.; Kangasmetsa J.; Lind P.; Lopez C.; Mauldin S.; Morin J.M.; Munroe J.; Noreen R.; Oberg B.; Sahlberg C.; Ternansky R.J.; Vrang L.; Zhang H.

Synthesis and Structure-Activity Relationship of Thiadiazole Derivatives, Novel Nonnucleoside Inhibitors of HIV-1
pp. 258-258(1)
Authors: Yokota T.; Fujiwara M.; Ijichi K.; Konno K.; Hanasaki Y.; Watanabe H.; Katsuura K.; Shirakawa S.; Takayama H.; Sakai S.; Shigeta S.; Baba M.

Mechanism of Anti-Human Immunodeficiency Virus (HIV) Action of Selected ATA-Polymer Analogues
pp. 258-258(1)
Authors: Reymen D.; Cushman M.; Wang P.; Witvrouw M.; Este J.; Neyts J.; De Clercq E.

3' -> 5' and 5' -> 5' Uridine-AZT Phosphodiester Dimers: Synthesis and In Vitro Anti-HIV Activities
pp. 259-259(1)
Authors: Imbach J.-L.; Pierra C.; Perigaud C.; Faraj A.; Sommadossi J.-P.; Aubertin A.-M.; Gosselin G.

Synthesis, Anti-Human Immunodeficiency Virus Activities, Cytotoxicities, and decomposition pathways of the bis(SATE)phosphotriester derivatives of AZT
pp. 259-259(1)
Authors: Imbach J.-L.; Lefebvre I.; Girardet J.-L.; Pompon A.; Xie M.-Y.; Sommadossi J.-P.; Aubertin A.-M.; Perigaud C.; Gosselin G.

Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion By Synthetic Phospholipid Analogs.
pp. 260-260(1)
Authors: Gray B.; Kucera L.; Thompson J.; Iyer N.; Poduval R.; Morris-Natschke S.; Ishaq K.

Characterization of siamycin I, an HIV fusion inhibitor
pp. 260-260(1)
Authors: Lin P.-F.; Samanta H.; Bechtold C.M.; Deminie C.; Alam M.; Riccardi K.; Rose R.E.; Patick A.K.; White R.; Colonno R.J.

Structure-Activity Relationship Studies for Various Oxathiin Carboxanilide Derivatives Modified in the Oxathiin Moiety Against Wild-Type and Mutant Human Immunodeficiency Virus Type 1 Strains.
pp. 261-261(1)
Authors: Balzarini J.; Brouwer W.G.; Dao D.C.; Felauer E.E.; Harrison W.A.; De Clercq E.; Karlsson A.

Pyrryl-Aryl-sulphones: synthesis and anti-HIV Activity.
pp. 261-261(1)
Authors: De Montis A.; Doa M.; Loi A.G.; La Colla P.; Artico M.; Silvestri R.; Stefancich G.; Massa S.

Effect of Specific Amino Acid Changes on the Anti-HIV Activity of NNRTIs: Confirmation of NNRTI-Resistant Virus Subgrouping and Selection of Compounds for Combination Therapy.
pp. 262-262(1)
Authors: Buckheit R.W.; Fliakas-Boltz V.; Pallansch L.A.

Unique Purine Crossover Activation Pathway for the Potent Anti-HIV Agent 1592U89.
pp. 262-262(1)
Authors: Faletto M.B.; Miller W.H.; Garvey E.P.; St. Clair M.H.; Hazen R.J.; Daluge S.M.; Good S.S.

Characterization of the anti-HIV-1 activity of DABOs.
pp. 263-263(1)
Authors: Loi A.G.; Tramontano E.; De Montis A.; Marongiu M.E.; Artico M.; Massa S.; Mai A.; La Colla P.

Anti-HIV Activity of Bovine Seminal RNase.
pp. 263-263(1)
Authors: La Colla P.; Lichino D.; Loi A.G.; D'Alessio G.

Creatine Phosphate Inhibits the Replication of HIV in Macrophages.
pp. 264-264(1)
Authors: Hansen L.J.; Kaddurah-Daouk R.

Zidovudine (AZT) Treatment Of Liver Cells Causes Accumulation Of Intracellular Lipid Droplets, And Phosphorylated Zidovudine Intracellularly Increases Lactate In Medium, And Inhibits Mitochondrial Dna Polymerase-.
pp. 264-264(1)
Authors: Lewis W.; Levine E.S.; Stretcher B.

AZT Metabolism and Toxicity: Application of 5-Azido-3'-Azido-2',3'-Dideoxyuridine Monophosphate, a Photoaffinity Analog of AZT-Monophosphate.
pp. 265-265(1)
Authors: Drake R.R.; Underwood L.J.; Jones R.; Battaglia E.; Mao F.; Rechtin T.M.; Cantu A.; Anderson S.; Radominska A.; Moyer M.P.

In Vitro Potency of Inhibition by Antiviral Drugs of Hematopoietic Progenitor Colony Formation Correlates with Exposure at Hemotoxic Levels in HIV Positive Humans.
pp. 265-265(1)
Authors: Dornsife R.E.; Averett D.R.

Cationic liposome-mediated delivery of anti-HIV-1 ribozyme to chronically infected cells.
pp. 266-266(1)
Authors: Konopka K.; Rossi J.J.; Felgner P.; Duzgunes N.

Metabolism of the carbocyclic analog of 2'-deoxyguanosine (CdG) in human cells.
pp. 266-266(1)
Authors: Allan P.W.; Parker W.B.; Arnett G.; Rose L.M.; Shaddix S.C.; Shewach D.S.; Fourel I.; Secrist J.A.; Montgomery J.A.; Shealy Y.F.; Bennett L.L.

Antiviral Resistance to Enantiomers of 2',3'-Dideoxycytidine Analogues -- Common Threads.
pp. 267-267(1)
Authors: Schinazi R.F.; Lloyd R.M.; McMillan A.; Gosselin G.; Imbach J.-L.; Chu C.K.; Sommadossi J.-P.

Kinetic Analysis of Human Immunodeficiency Virus Type-1 Reverse Transcriptase with Mutations at Methionine 184 in the Highly Conserved YMDD Region
pp. 267-267(1)
Authors: Wilson J.; Caligan B.; Aulabaugh A.; McPherson S.; Wakefield J.; Jablonski S.; Morrow C.; Furman P.; Reardon J.

Characterization of HIV-- 1 Reverse Transcriptase Encoding Mutations at the Amino Acid Residues 161 and 208 Involved in Phosphonoformate Resistance
pp. 268-268(1)
Authors: Tramontano E.; Piras G.; Congeddu E.; Mellors J.; Bazmi H.; La Colla P.

In vitro selection of HIV-1 resistance to ddI is not as efficient as for other antiretroviral drugs and yields virus which shows reduced cytophatic activity.
pp. 268-268(1)
Authors: Dianzani F.; Antonelli G.; Bellarosa D.; Bambacioni F.; Riva E.; Gentile A.; Turriziani O.

3-Dimensional structure studies of Thiadiazole-derivatives for anti-HIV-1 RT activity
pp. 269-269(1)
Authors: Nagano H.; Ijichi K.; Matsumoto Y.; Fujiwara M.; Hanasaki Y.; Watanabe H.; Katsuura M.; Shirakawa S.; Takayama H.; Sakai S.; Shigeta S.; Konno K.; Baba M.; Matsushima M.; Yokota T.

Characterization of a cellular line expressing a defect of thymidine kinase activity and displaying resistance to the antiviral activity of AZT.
pp. 269-269(1)
Authors: Antonelli G.; Turriziani O.; Strosselli S.; Verri A.; Cianfriglia M.; Riva E.; Simeoni E.; Dianzani F.

Kinetic Analysis of the Interaction of Inhibitors with RMuLV and Human Immunodeficiency Virus (HIV) Reverse Transcriptases (RTs).
pp. 270-270(1)
Authors: Cherrington J.M.; Allen S.J.W.; Kunder S.C.; Ussery M.A.; Chen M.S.

Cloning, Purification and Biochemical Characterization of HIV - 2 Reverse Transcriptase (RT) and Comparison with Endogenous HIV - 2 RT.
pp. 270-270(1)
Authors: Piras G.; Tramontano E.; Putzolu M.; Casula R.; La Colla P.

Homology modeling and molecular dynamics simulation studies of a hypothetical HIV-1 DNA binding protein and potential E2-like target site in the HIV-1 LTR.
pp. 271-271(1)
Authors: Ramanathan C.S.; Stewart D.E.; Taylor E.W.

Do some viruses encode selenoproteins? - Assessment of the theory in the light of current theoretical, experimental and clinical data.
pp. 271-271(1)
Authors: Taylor E.W.; Ramanathan C.S.; Nadimpalli R.G.; Schinazi R.F.

Anti-retroviral activities of baicalin in vitro and in vivo
pp. 272-272(1)
Authors: Chen H.; Zhang X.-q.; Teng L.; Wu X.-x.; Lu Y.-z.; Tang X.-s.; Yang X.-s.; Yan X.-g.

Sequences within the HIV-1 LTR Required for Strand Transfer By Integrase In Vitro
pp. 272-272(1)
Authors: Hazuda D.J.; Felock P.J.; LaFemina R.L.; Wolfe A.L.

A Retrometabolic concept: The pronucleotide approach
pp. 273-273(1)
Authors: Imbach J.-L.; Perigaud C.; Gosselin G.; Obert G.; Aubertin A.-M.; Kirn A.

Suppression of Hematopoietic Support Function is Associate with Over-Expression of IL-4 and TGF1 in LP-BM5 MuLV Infected Stromal Cell Lines.
pp. 273-273(1)
Authors: Gallicchio V.S.; Tse K.-F.; Morrow J.K.; Hughes N.K.

Evaluation of Anti-AIDS Drugs in Conventional Mice Implanted with a Permeable Membrane (Hollow Fiber) Device Containing Human T Cells Infected with HIV.
pp. 274-274(1)
Authors: Allen L.B.; Quenelle D.C.; Taylor B.A.; Bowdon B.J.; Keith K.; Brazier A.D.; Shannon W.M.; Dunleavy K.E.

In Vitro and In Vivo Enhancement of ddI Activity against Rauscher Murine Leukemia Virus (RMuLV) by Ribavirin
pp. 274-274(1)
Authors: Quenelle D.C.; Allen L.B.; Westbrook L.; Taylor B.A.; Prichard M.N.; Brazier A.D.; Hollingshead M.G.; Shannon W.M.

Antiretroviral Activity of Ribonucleotide Reductase Inhibitors Hydroxyurea, Didox and Trimidox in the in vivo Rauscher Murine Leukemia Virus (RMuLV) Model.
pp. 275-275(1)
Authors: Black P.L.; Kunder S.C.; Hall B.E.; Elford H.L.; Ussery M.A.

Phosphorylation of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is greater in macrophages than in replicating lymphocytes and fibroblasts
pp. 275-275(1)
Authors: Balestra E.; Perno C.; Aquaro S.; Lazzarino G.; Tavazzi B.; Di Pierro D.; Calio R.; Balzarini J.; De Clercq E.

PMEA has immunomodulatory activity and inhibits reverse transcriptase in the Rauscher murine leukemia virus (RMuLV) model.
pp. 276-276(1)
Authors: Kunder S.C.; Black P.L.; Hall B.E.; Ussery M.A.

Antiviral Efficacy in Mice of Oral Bis(POM)-PMEA, the Bis(pivaloyloxymethyl) Ester Prodrug of 9-(2-Phosphonylmethoxyethyl)adenine.
pp. 276-276(1)
Authors: Bischofberger N.; Naesens L.; Neyts J.; Balzarini J.; De Clercq E.

n-Docosanol prevents vaginal transmission of SIVmac251 in rhesus macaques.
pp. 277-277(1)
Authors: Miller C.J.; Gersten M.J.; Davis R.C.; Katz D.H.

Pharmacokinetics in Mice of Bis(POM)-PMEA, the Bis(pivaloyloxymethyl) Ester Prodrug of 9-(2-Phosphonylmethoxyethyl)adenine.
pp. 277-277(1)
Authors: Bischofberger N.; Naesens L.; Neyts J.; Balzarini J.; De Clercq E.

Study of Human Immunodeficiency Virus Resistance to the Acyclic Nucleoside Phosphonate Analogs.
pp. 278-278(1)
Authors: Fridland A.; Aduma P.; Sarkissian N.; Srinivas R.V.

Enzymatic phosphorylation of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in Drug sensitive and Resistant Cells.
pp. 278-278(1)
Authors: Robbins B.; Connelly M.; Greenhaw J.; Fridland A.

Negatively Charged Human Serum Albumins: A Novel Class of Polyanionic Proteins with a Potent Anti-HIV-I Activity
pp. 279-279(1)
Authors: Swart P.J.; Meijer D.K.F.

Preparation and Characterization of Conjugates of (Modified) Human Serum Albumin Liposomes: Drug Carriers with an Intrinsic Anti-HIV Activity
pp. 279-279(1)
Authors: Kamps J.A.a.M.; Swart P.J.; Morselt H.; Meijer D.K.F.; Scherphof G.L.

Negatively Charged Human Serum Albumins: Inhibition of Replication of Primary HIV-1 Isolates and Biomolecular Interaction with Gp120
pp. 280-280(1)
Authors: Kuipers M.E.; Swart P.J.; Groenink M.; Huisman J.G.; Schuitemaker H.; Meijer D.K.F.

Pharmacokinetics and anti-HIV-1 Efficacy of Negatively Charged Human Serum Albumins in Mice
pp. 280-280(1)
Authors: Kuipers M.E.; Swart P.J.; Schutten M.; Smit C.; Osterhaus A.D.M.E.; Meijer D.K.F.

Further Studies into the Mechanism of Interaction of Negatively Charged Human Serum Albumins with the V3 Loop of the HIV-1 Envelope Protein Gp120.
pp. 281-281(1)
Authors: Kuipers M.E.; Huisman J.G.; Swart P.J.; Schuitemaker H.; Meijer D.K.F.

2',3'-Dideoxycytidine 5'-triphosphate analogs as substrate for human DNA polymerases: implication for the mechanism of toxicity
pp. 281-281(1)
Authors: Kukhanova M.; Liu S.H.; Chu C.K.; Cheng Y.-C.

Effect of Protein Binding on the Pharmacodynamics of an HIV Protease Inhibitor.
pp. 282-282(1)
Authors: AIDS Clinical Trials Group ACTG 282 Study Team; Flexner C.; Richman D.D.; Bryant M.; Karim A.; Yeramian P.; Meehan P.; Haubrich R.; Para M.F.; Fischl M.A.

Red-blood cells mediated drug delivery to phagocytic cells as a selective therapeutic approach to infections by HIV and herpesviruses
pp. 282-282(1)
Authors: Perno C.; Balestra E.; Lazzarino G.; Tavazzi B.; Aquaro S.; Di Pierro D.; Calio R.; Santoro N.; Pozzi D.; Grimaldi S.

Membrane Permeation Characteristics of the Structurally Related Anti-HIV Agents 1592U89 and (-)-Carbovir in Human Erythrocytes and Human T-Lymphoblastoid CD4⁺ CEM Cells.
pp. 283-283(1)
Authors: Zimmerman T.P.; Mahony W.B.; Domin B.A.; Prus. K.L.

Distribution to the brain, protein binding and physico-chemical properties of 5-substituted 3'-fluoro-uridine derivatives, studied by microdialysis
pp. 283-283(1)
Authors: Borg N.; Stahle L.; Zhou X.-X.

Pharmacokinetics of 3'-fluoro-guanosine (FLG) in cynomolgus monkeys
pp. 284-284(1)
Authors: Borg N.; Bottiger D.; Zhou X.-X.; Johansson N.-G.; Oberg B.; Stahle L.

Competitive elisa for D4T: application to clinical pharmacology.
pp. 284-284(1)
Authors: Guedj R.; Ferrua B.; Tran T.; Quaranta J.; Kubar J.; Rotpin C.; Condom R.; Sinet M.; Durand J.

Zidovudine-Uridine Dimer and its Hexadecyl Ester: Synthesis, Antiviral Evaluation and Pharmacokinetics.
pp. 285-285(1)
Authors: Agrawal K.C.; Lu Q.; Brakta M.; Bandera N.; Gogu S.R.; Garry R.F.

Application of microdialysis to the study of antiviral drug pharmacokinetics in humans: validation of subcutaneous extracellular sampling of zidovudine
pp. 285-285(1)
Authors: Stahle L.; Sandstrom E.

One-Month Oral Toxicity Studies of A Protease Inhibitor (ABT-987) in Rats and Dogs.
pp. 286-286(1)
Authors: Yang C.; Gemzik B.; Ewing P.; Pratt M.; Friedman M.; Cusick P.; Krasula R.; Patterson R.

Chemoimmunotherapy (CI) by Thiophenoyl Urea(TUR) & Nonvirion antigen vaccine (NVA) for AIDS patients.
pp. 286-286(1)
Authors: Hollinshead A.; Wash G.

Safe coadministration of Famciclovir and Zidovudine to HIV Positive Patients
pp. 287-287(1)
Authors: Siederer S.; Scott S.; Rousseau F.; Fowles S.; Sparrow P.; Lascoux C.; Lehner V.; Serini D.

Anti-HIV Agent 935U83 - Preliminary Clinical Assessment.
pp. 287-287(1)
Authors: Daluge S.M.; St. Clair M.H.; Wang L.; Savina P.M.; Spreen W.; Krenitsky T.A.; Yeo J.; Larder B.A.; Parry N.; Purifoy D.J.M.

L-FMAU, A Novel Anti-HBV and Anti-EBV Agent.
pp. 288-288(1)
Authors: Chu C.K.; Ma T.W.; Shanmuganathan K.; Wright J.D.; Boudinot F.D.; Faraj A.; Sommadossi J.-P.; Pai S.B.; Yao G.-Q.; Cheng Y.-C.

2'-Deoxy-4'-Thio Purine Nucleosides as Potent Inhibitors of HBV and HCMV.
pp. 288-288(1)
Authors: Koszalka G.W.; Freeman G.A.; Short S.A.; Harvey R.; Jansen R.; Szczech G.; Van Draanen N.A.

Colorimetric Assay System for Screening Antiviral Compounds against Hepatitis B Virus.
pp. 289-289(1)
Authors: Sudo K.; Konno K.; Sato H.; Yokota T.; Shigeta S.

Novel Assay System for Hepatitis C Virus Serine Protease Inhibitors
pp. 289-289(1)
Authors: Inoue H.; Hirowatari Y.; Hijikata M.; Yokota T.; Shimotohno K.

Long Term Antiviral Combination Chemotherapy for Duck Hepatitis B Virus Infection using Ganciclovir and Nalidixic Acid in vivo.
pp. 290-290(1)
Authors: Luscombe C.; Wang Y.; Pedersen J.; Locarnini S.

Efficacy of treatment with small dosage Interferon for Hepatitis C virus
pp. 290-290(1)
Authors: Zhangqi W.; Shengqing L.; Luokeng P.

Differential Effects on the Binding of the Transcription Factor, AP-1, to its Cognate DNA Sequence Containing the Nucleoside analog FIAU
pp. 291-291(1)
Authors: Staschke K.A.; Baxter A.J.; Scheuring J.C.; Mabry T.E.; Colacino J.M.

Chain Terminated Hepadnavirus Genomes are Released as Complete Extracellular Virions: Are Serum Virion DNA Levels a True Measure of Drug Efficacy?
pp. 291-291(1)
Authors: Korba B.E.; Gerin J.L.

Effect of Nucleosides on Mitochondrial Functions in HepG2 Cells.
pp. 292-292(1)
Authors: Cui L.; Schinazi R.F.; Gosselin G.; Imbach J.-L.; Chu C.K.; Rando R.F.; Sommadossi J.-P.

Frequency of UL97 Mutations Related to Ganciclovir Resistance in Clinical CMV Isolates.
pp. 293-293(1)
Authors: Drew W.L.; Guentzel S.; Michels K.R.; Miner R.C.; Chou S.

Phosphonoacid Prodrugs with Greatly Increased Antiviral Activity in HCMV-Infected Cells, in vitro.
pp. 294-294(1)
Authors: Hostetler K.Y.; Aldern K.A.; Kini G.D.; Wheeler C.J.; Sridhar C.N.

Synthesis and Antiviral Activity of Novel Phosphonomethyl Ether Nucleosides.
pp. 294-294(1)
Authors: Bischofberger N.; Kern E.R.; Chen M.S.; Barkhimer D.B.; Cherrington J.M.; Dougherty J.P.; Kim C.U.; Lew W.; Mendel D.B.; Moon K.; Mulato A.S.; Williams M.A.; Yang W.

Potent Anti-Viral Activity of an Antisense Oligonucleotide Complementary to the Intron-Exon Boundary of Human Cytomegalovirus Genes UL36/37.
pp. 295-295(1)
Authors: Pari G.S.; Field A.K.; Smith J.A.

Inhibition of HCMV DNA Processing by a New Class of Anti-HCMV Compounds (Benzimidazole Ribosides) is Mediated Through the UL89 Gene Product
pp. 295-295(1)
Authors: Underwood M.R.; Stanat S.C.; Townsend L.B.; Drach J.C.; Biron K.K.

Sequential Ascending Multiple-dose Safety and Pharmacokinetic Study of Oral Lobucavir (BMS-180194) in Asymptomatic Volunteers Seropositive for HIV and CMV.
pp. 296-296(1)
Authors: Petty B.; Wachsman M.; Jordan M.; Burgee H.; DeHertogh D.; Collins D.; Summerill R.; Jabs D.; Dunn J.; Hellmann N.; Kringstad B.; Fletcher C.; Smaldone L.; Lietman P.; Stewart M.

Inhibitors of Varicella Zoster Virus Thymidine Kinase.
pp. 296-296(1)
Authors: Wright G.E.; Xu H.; Sou T.; Focher F.; Verri A.; Spadari S.

A Randomized, Controlled Trial of Zovirax (Acyclovir, ACV) Versus Netivudine for the Treatment of Herpes Zoster.
pp. 297-297(1)
Authors: The International Zoster Study Group; Fiddian A.

Anti-influenzavirus-activities of polyoxometalates
pp. 298-298(1)
Authors: Shigeta S.; Mori S.; Watanabe J.; Yamase T.; Hill C.L.; Schinazi R.F.

Synthetic Peptides from Conserved Regions of RSV, HPIV-3, and MeV Fusion Proteins are Potent Antivirals (Inhibitors of Viral Fusion).
pp. 298-298(1)
Authors: Petteway S.R.; Barney S.; Lambert A.L.; Guthrie K.; Bucy T.; Erickson J.; Merutka G.; Lambert D.M.

Prophylactic Therapy of Respiratory Syncytial Virus (RSV) Infection of Rhesus Monkeys with Monoclonal IgA Antibody to RSV
pp. 299-299(1)
Authors: Traina-Dorge V.; Soike K.; Zhang J.-Y.; Mack P.; Monath T.; Weltzin R.

Coxsackievirus B3 Mutants Resistant to WIN 63843 Are Attenuated For Virulence In Mice: Molecular Analysis of the Drug Resistant Phenotype.
pp. 300-300(1)
Authors: Groarke J.M.; McKinlay M.A.; Dutko F.J.; Pevear D.C.

Twice daily intranasal GG167 for experimental influenza A.
pp. 300-300(1)
Authors: Hayden F.; Treanor J.; Esinhart J.; Eason C.; Hussey E.

Inhibition of Ebola Virus by S-Adenosylhomocysteine Hydrolase Inhibitors
pp. 301-301(1)
Authors: Huggins J.W.; Zhang Z.X.; Davis K.; Coulombe R.A.

Antiviral and Immunomodulating Activities of the Imidazoquinoline S-28463.
pp. 301-301(1)
Authors: Imbertson L.M.; Beaurline J.M.; Gerster J.F.; Gibson S.J.; Horton V.L.; Miller R.L.; Myhre P.E.; Reiter M.J.; Tamulinas C.B.; Tomai M.A.

Safety of Didanosine plus Stavudine Combination Therapy in HIV-infected Subjects in a Pilot Randomized Double-blinded Trial.
pp. 302-302(1)
Authors: Pollard R.; Hardy D.; Peterson D.; Pottage J.; Hellmann N.; Skovronski J.; Reynolds L.; Rutkiewicz V.; Ogorzalek S.; McLaren C.; Dunkle L.

Oral brivudin versus intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial
pp. 302-302(1)
Authors: Wutzler P.; Wutke K.; Farber I.; De Clercq E.

The Efficacy of Steroids and Acyclovir Therapy of Herpes Zoster in the Elderly.
pp. 303-303(1)
Authors: NIAID Collaborative Antiviral Study Group CASG; Whitley R.; Weiss H.; Gnann J.; Tyring S.; Wolf J.; Pollard R.; Mertz G.; Pappas P.; Laughlin C.; Sherrill L.; Schlupner C.; Soong S.

Stereoselective Synthesis of (S)- and (R)-Penciclovir Triphosphate and their Activity Against Viral Enzymes.
pp. 304-304(1)
Authors: Lesnikowski Z.J.; Juodawlkis A.S.; Lloyd R.M.; Schinazi R.F.

Synthesis of acyclic nucleotide analogues derived from 2-(aminomethyl)purine bases.
pp. 305-305(1)
Authors: Holy A.; Hocek M.; Balzarini J.; De Clercq E.

Synthesis and biological evaluation of new carbocyclic 2'3'-didehydro-2',3'-dideoxy and 3'-deoxy-2'-fluoropyrimidine and purinenucleosides
pp. 305-305(1)
Authors: Guedj R.; Suhas E.E.E.; Frogier P.R.T.; Condom R.; Challand S.R.; Kirn A.; Aubertin A.M.

Potent Topical Anti-Herpes Activity of a Lipophilic Phosphorus Prodrug for the Antiviral Agent PMEA
pp. 306-306(1)
Authors: Glazier A.; Yanachkova M.; Yanachkov I.; Wright G.E.; Palmer J.; Hartline C.; Kern E.R.

Sulfated xylogalactans from marine algae useful as anti HSV-1 agents.
pp. 306-306(1)
Authors: Damonte E.B.; Matulewicz M.C.; Cerezo A.S.; Coto C.E.

Herpes Thymidine Kinase Inhibitors: Resolution and Enantioselective Synthesis of L-653, 180 and Water-soluble Prodrugs
pp. 307-307(1)
Authors: Von Langen D.J.; Karkas J.D.; Bostedor R.; Liou R.; Tolman R.L.

HSV-Thymidine Kinase: a molecular target for transfection imaging in gene therapy of cancer.
pp. 307-307(1)
Authors: Wiebe L.I.; Knaus E.E.; Morin K.W.

Herpesvirus Sensitivity to Zovirax (Acyclovir, ACV) and Other Nucleoside Analogues.
pp. 308-308(1)
Authors: Collins P.; Darby G.

In Vitro Activity of Bile Acids on Herpes Simplex Virus Type-2 (HSV-2) Infection.
pp. 308-308(1)
Authors: Reising S.; Quinn K.; Stanberry L.

The Development of an In Vitro Antiviral Susceptibility Assay Using Alamar Blue.
pp. 309-309(1)
Authors: Belhorn T.H.; Azar S.

Development of Anti-HSV Screening System Using Suspension Cell line and Screening Several Nucleoside Analogues in This Method
pp. 309-309(1)
Authors: Kira T.; Kakefuda A.; Awano H.; Shuto S.; Matsuda A.; Baba M.; Saneyoshi M.; Shigeta S.

The in vitro Activity of Cidofovir against Acyclovir-resistant and Foscarnet-resistant Herpes Simplex Virus (HSV) Isolates.
pp. 310-310(1)
Authors: Safrin S.; Abarbarchuk E.; Palacios E.

Comparative Evaluation of the Plaque Reduction Assay and a Microplate ELISA Test for Antiviral Susceptibility Testing of Herpes Simplex Virus (HSV) Isolates.
pp. 310-310(1)
Authors: Safrin S.; Palacios E.; Leahy B.

Interactions of reproductive ability of herpes simplex virus (HSV) type I and its variants, resistant to acyclovir (ACV) and phosphonoacetic acid (PAA) with proliferative activity of VERO cells.
pp. 311-311(1)
Authors: Nikolaeva S.N.; Boreko E.I.; Erokhina I.R.; Votyakov V.I.

Antiviral activity of nucleoside derivatives against acyclovir-resistant mutants of herpes simplex virus type 1
pp. 311-311(1)
Authors: Lee C.-K.; Kim J.H.; Kim H.S.

Antiviral Drug Susceptibility of Herpes Simplex Type 1 (HSV-1) Strains Emerging Under the Selective Pressure of (S)-1-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine (HPMPC) in vitro
pp. 312-312(1)
Authors: Andrei G.; Snoeck R.; De Clercq E.

Isolation and Initial Characterization of a Herpes Simplex Virus Type 2 (HSV-2) Strain With Decreased Sensitivity to Cidofovir.
pp. 312-312(1)
Authors: Mendel D.B.; Barkhimer D.B.; Kern E.R.; Chen M.S.

Acyclovir, as a tool to differentiate between mutants of herpes simplex virus, in mixed infections.
pp. 313-313(1)
Authors: Katz E.; Keywan K.

Intracellular Metabolism of the Novel Anti-Herpesvirus Agent 2-Amino-7-[1,3-dihydroxy-2-propoxy)methyl]purine Compound S2242 in Non-Infected and Herpesvirus-Infected Cells.
pp. 313-313(1)
Authors: Neyts J.; Balzarini J.; Andrei G.; Reymen D.; Snoeck R.; Jahne G.; Winkler I.; De Clercq E.

Purification and Photoaffinity Labeling of Herpes Simplex Virus Type-1 Thymidine Kinase
pp. 314-314(1)
Authors: Rechtin T.M.; Black M.E.; Mao F.; Drake R.R.

Improved Purification of the HSV Protease Catalytic Domain using Immunoaffinity:
pp. 314-314(1)
Authors: McKercher G.; Thibeault D.; Bonneau P.R.; Krogsrud R.L.; Lawetz C.; Lagace L.; Massariol M.-J.; Cordingley M.G.

Peptide Disruption of Protein-Protein Complexes: a Novel Strategy for Antiviral Therapy
pp. 315-315(1)
Authors: Palu G.; Marcello A.; Loregian A.; Pizzato M.

Activity of Hydroxyurea (HU) in Combination with Several Antiviral Nucleosides Against in vitro Replication of Herpes Simplex Type 1 (HSV-1) and Type 2 (HSV-2) and Varicella-Zoster Virus (VZV)
pp. 315-315(1)
Authors: Snoeck R.; Andrei G.; De Clercq E.

Effect of recombinant human and mouse interferons on herpes simplex virus type 1 replication in vitro and in vivo.
pp. 316-316(1)
Authors: Wintergerst U.; Gangemi J.D.; Whitley R.J.; Kern E.R.; Chatterjee S.

Antiviral properties of sterically hindered phenol derivatives.
pp. 316-316(1)
Authors: Andreeva O.T.; Votyakov V.I.; Zhelobkovich V.E.; Petrikevich D.K.; Kunevich E.C.; Timoshchuck V.A.; Shadyro O.I.

Influence of the Size of the Virus Inoculum on the Efficacy of Acyclovir (ACV) and Implications for the Treatment of Herpes Simplex Labialis.
pp. 317-317(1)
Authors: McKeough M.B.; Spruance S.L.

Antiviral Activity of Phosphinic Cyclocreatine (2-iminoimidazolidine-1-Methyl Phosphinic Acid) Against HCMV and HSV-1.
pp. 317-317(1)
Authors: Mulamba B.G.; Hansen L.J.; Kaddurah-DaouK R.

Rapid Assay for Determining the Mode of Action of Compounds Effective Against Human Cytomegalovirus (HCMV).
pp. 318-318(1)
Authors: McSharry J.; Chutkowski C.

Rapid determination of antiviral sensitivity of human cytomegalovirus
pp. 318-318(1)
Authors: Stahle E.L.; Sundqvist V.; Linde A.; Wahren B.

Sensitivities of Human Cytomegalovirus (HCMV) Clinical Isolates to Cidofovir.
pp. 319-319(1)
Authors: Cherrington J.M.; Allen S.J.W.; Mulato A.S.; Miner R.; Drew W.L.; Chen M.S.

Selection and Characterization of HCMV Resistant to the Benzimidazole Ribonucleoside TCRB.
pp. 319-319(1)
Authors: Bush P.M.; Turk S.R.; Ptak R.G.; Albayya F.P.; Westerman A.C.; Townsend L.B.; Drach J.C.

Human Cytomegalovirus (HCMV) Strains Selected under Selective Pressure of Phosphonoformate (PFA) are Resistant for Both PFA and Phosphonylmethoxyethyl (PME) Derivatives in vitro
pp. 320-320(1)
Authors: Snoeck R.; Andrei G.; De Clercq E.

Effects of Desferrioxamine on Human Cytomegalovirus Replication and Expression of HLA Antigens and Adhesion Molecules in Human Vascular Endothelial Cells
pp. 320-320(1)
Authors: Gumbel H.; Cinatl J.; Scholz M.; Vogel J.-U.; Weber B.; Cinatl J.; Rabenau H.; Encke A.; Doerr H.-W.

The Consequence of Incorporation of (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine by Human Cytomegalovirus DNA Polymerase on DNA Elongation.
pp. 321-321(1)
Authors: Xiong X.F.; Smith J.L.; Chen M.S.

Specific Anti-Cytomegaloviral Activity of Methotrexate Associated with Preferential Accumulation of Drug by Infected Cells.
pp. 321-321(1)
Authors: Wachsman M.; Hamzeh F.M.; Saito H.; Lietman P.S.

Direct Quantitation of CMV DNA in leukocytes by bDNA Signal Amplification Assay.
pp. 322-322(1)
Authors: Kolberg J.A.; Hoo B.; Miner R.; Kelso R.; Wiegand J.; Chernoff D.; Jekic-McMullen D.; Drew W.L.

Characterization of the guinea pig cytomegalovirus UL97 gene homologue.
pp. 322-322(1)
Authors: Fox D.S.; Schleiss M.R.

Selective elimination of cytomegalovirus infected cells by immunotoxins targeted with various antibodies linked to ricin A chain or gelonin.
pp. 323-323(1)
Authors: Barnett B.; Smee D.; Sidwell R.

Activities of Anti-Murine Cytomegalovirus (MCMV) Immunotoxins Used Alone or in Combination with Antiviral Agents Against MCMV Infections.
pp. 323-323(1)
Authors: Smee D.F.; Okleberry K.M.; Barnett B.B.; Sidwell R.W.

Combination of Azidothymidine (AZT) with (E)-5-(2-Bromovinyl)-2'-Deoxyuridine (BVDU) Leads to Inhibition of the in vitro Replication of Herpes Simplex Virus Type 1 (HSV-1), Type 2 (HSV-2) and Varicella-Zoster Virus (VZV) Strains that Are Deficient in Thymidine Kinase (TK) Activity
pp. 324-324(1)
Authors: Andrei G.; Snoeck R.; Balzarini J.; De Clercq E.

Analysis of mutations in the thymidine kinase gene of varicella-zoster virus associated with resistance to 5-iodo-2'-deoxyuridine (IDU) and 5-bromo-2'-deoxyuridine (BrDU).
pp. 324-324(1)
Authors: Kodama E.; Mori S.; Shigeta S.

QC-PCR Accurate Determination of Rabbit Genomic DNA: Evaluation of VZV Load in the Rabbit Ocular Infection Model.
pp. 325-325(1)
Authors: Zhu Q.; Piatak M.; Guo J.; Yamamoto S.; Pavan-Langston D.; Dunkel E.

Some Nucleoside Analogs With Anti-Human Immunodeficiency Virus Activity Inhibit Replication of Epstein-Barr Virus
pp. 325-325(1)
Authors: Mar E.-C.; Chu C.K.; Lin J.-C.

Antiviral Activity of Selected Nucleoside Analogues against Human Herpes Virus Type 6
pp. 326-326(1)
Authors: Reymen D.; Naesens L.; Balzarini J.; Holy A.; De Clercq E.

Antiviral activity of compounds against human herpesvirus 6
pp. 326-326(1)
Authors: Takahashi K.; Shigeta S.

Evaluation of Antiviral Agents Against HHV-6 and HHV-7 in Human Cord Blood Cells.
pp. 327-327(1)
Authors: Feorino P.M.; Black J.; Kite-Powell K.; Burns D.; Schinazi R.F.

Spontaneous Reactivation of Acyclovir Resistant (ACV^r) Thymidine Kinase Deficient (TK^-) Herpes Simplex Virus Type 2 (HSV 2) Is Still Dependent Upon Viral TK Expression.
pp. 327-327(1)
Authors: Sasadeusz J.J.; Safrin S.; Sacks S.L.

Comparative effects of famciclovir and valaciclovir on cutaneous and neurological HSV-1 infection in normal and immunocompromised mice.
pp. 328-328(1)
Authors: Thackray A.M.; Field H.J.

Comparison of the Antiviral Efficacy of Acyclovir and Penciclovir in Topically Treated HSV-Infected HRS/J Mice.
pp. 328-328(1)
Author: Selleseth D.W.

Comparison of Efficacy and Toxicity of HPMPC and Cyclic HPMPC in Animal Models for Severe Herpesvirus Infections.
pp. 329-329(1)
Authors: Kern E.R.; Palmer J.; Hartline C.; Vogt P.E.

Hydrocephalus Induction in Mice Infected with Herpes Simplex Virus Type 2 after Antiviral Treatment.
pp. 329-329(1)
Authors: Yao X.; Schinazi R.F.

Effect of HBPG on the Clinical Recurrences of Ocular Herpetic Keratitis in Squirrel Monkeys.
pp. 330-330(1)
Authors: Kaufman H.; Varnell E.; Wright G.; Xu H.

Efficacy of Peptide T in the Rabbit Model of HSV-1-Induced Keratitis.
pp. 330-330(1)
Authors: Dunkel E.; Michaelis J.; Sleigh M.; Guo J.; Geary P.; Zhu Q.

Potentiating Effect of Dextran Sulphate on the Antiviral Activity of Acyclovir and BVDU in the Treatment of Herpetic Keratitis in Rabbits.
pp. 331-331(1)
Author: Pancheva S.N.

Peptidomimetic Ribonucleotide Reductase Inhibitors in the Treatment of Herpes Simplex Keratitis in Mice.
pp. 331-331(1)
Authors: Garneau M.; Pare M.-C.; Nawoot S.; Jaramillo J.; Deziel R.

Significance of High Skin Fluxes Produced By Acyclovir Topical Formulations for Achieving Therapeutic Levels of Drug at the Target Site in the Treatment of Cutaneous HSV-1 Infections in Hairless Mice: A Closer Look at the C^* Concept.
pp. 332-332(1)
Authors: Patel P.J.; Ghanem A.-H.; Higuchi W.I.; Hsu J.; Srinivasan V.; Kern E.R.

Lidakol Cream vs Zovirax Ointment for the Treatment of Experimental Dorsal Cutaneous Herpes Simplex Virus Type 1 (HSV-1) Infection in the Guinea Pig.
pp. 332-332(1)
Authors: McKeough M.B.; Spruance S.L.

Comparison of n-Docosanol Cream (LIDAKOL^TM) with Acyclovir Ointment (Zovirax^TM) in the Inhibition of Cutaneous Herpes Simplex Virus (HSV) Infections in Two Guinea Pig Model Systems.
pp. 333-333(1)
Authors: Marcelletti J.F.; McFadden R.R.; Khalil M.H.; Pope L.E.; Davis R.C.; Katz L.R.; Katz D.H.

Effect of Polyanionic Compounds on Intracutaneous and Intravaginal Herpes Virus Infection in Mice: Impact on the Search for Vaginal Microbicides.
pp. 333-333(1)
Authors: Neyts J.; De Clercq E.

Prevention and Treatment of Experimental Genital Herpes Simplex Virus Type 2 (HSV-2) Infections with Topical HPMPC.
pp. 334-334(1)
Authors: Palmer J.; Vogt P.E.; Kern E.R.

Evaluation of CRT Healing Components in two different Topically Treated Cold Sore Animal Models.
pp. 334-334(1)
Authors: Martin A.; Kern E.R.; Sheridan J.

Pathogenesis of Drug Resistant Clinical HSV-2 Isolates in the Guinea Pig Model of Genital Herpes.
pp. 335-335(1)
Authors: Bourne N.; Stanberry L.; Ireland J.; Bernstein D.

Civamide (CIV) Treatment of Primary and Recurrent Experimental Genital Herpes.
pp. 335-335(1)
Authors: Bourne N.; Bernstein D.; Stanberry L.

Effect of S-28463 in reducing recurrent genital HSV-2 in guinea pigs.
pp. 336-336(1)
Authors: Bernstein D.I.; Miller R.L.; Tepe E.; Mester J.C.; Harrison C.J.

Psychosocial impact of genital herpes in guinea pigs: effect of 0-2B914 therapy.
pp. 336-336(1)
Authors: Bernstein D.; Bourne N.; Rosenthal S.; Stanberry L.

The Phosphonate Ganciclovir Derivative SR 3745A Demonstrates Severe Toxicity In Cell Culture And In Guinea Pigs.
pp. 337-337(1)
Authors: Levine E.S.; Bravo F.J.; Bernstein D.I.; Stanberry L.R.; Lewis W.

Human Bone Marrow Toxicity of a Non-nucleoside Pyrrolo[2,3-d]pyrimidine.
pp. 337-337(1)
Authors: Nassiri M.R.; Taichman R.S.; Renau T.E.; Emerson S.G.; Townsend L.B.; Drach J.C.

Qualitative and Quantitative Differences between Intracellular Penciclovir (PCV) Triphosphate (PCVTP) and Acyclovir (ACV) Triphosphate (ACVTP) in a Human Schwannoma Cell Line (SW) Infected With Varicella Zoster Virus (VZV).
pp. 338-338(1)
Authors: Bebault G.M.; Wall R.A.; Rennie B.A.; Smyrnis E.M.; Sacks S.L.

A Pharmacokinetic/Pharmacodynamic Approach for the Comparison of Penciclovir and Acyclovir: Utilization of an in vitro model which Simulates in vivo Pharmacokinetics.
pp. 338-338(1)
Authors: Hamzeh F.M.; Schaad H.J.; Lietman P.S.

Pharmacokinetics and distribution of penciclovir to the brain and muscle in the rat studied by microdialysis.
pp. 339-339(1)
Authors: Stahle L.; Borg N.

High Bioavailability and Rapid Distribution of Penciclovir Following an Oral Dose of Famciclovir
pp. 339-339(1)
Authors: Siederer S.; Pue M.A.; Fairless A.J.; Hucker R.S.; Collie H.; Sourgens H.

Pharmacokinetics of Penciclovir following Oral Famciclovir in Subjects with Mild Renal Impairment.
pp. 340-340(1)
Authors: Scott S.; Siederer S.

Tissue Distribution and Bioavailability of Cyclic HPMPC, an Intracellular Prodrug of HPMPC
pp. 340-340(1)
Authors: Lee W.A.; Shaw J.-P.; Bidgood A.; Eisenberg E.; Cundy K.C.

Efficacy and Pharmacokinetics of Topical HPMPC in a Guinea Pig Model of Genital Herpes.
pp. 341-341(1)
Authors: Kern E.R.; Palmer J.; Vogt P.E.; Cundy K.; Hitchcock M.J.M.; Sommadossi J.-P.

Inhibition of Dihydropyrimidine Dehydrogenase by 5-(E-2-Bromovinyl)uracil (BV-Ura) and Recovery of Rat Liver DPD Activity after Administration of BV-Ura or Sorivudine
pp. 341-341(1)
Authors: Machida H.; Endo K.; Watanabe Y.; Ashida N.; Sakata S.

Development of HSV-2 Type-Specific Antibodies to Glycoprotein B In HSV-2 Seronegative Individuals Following Immunization with a Recombinant gB2/gD2/Adjuvant Vaccine.
pp. 342-342(1)
Authors: Goade D.; Bell R.; Mertz G.J.; Burke R.; Langenberg A.G.M.; Jenison S.

Preclinical Safety Assessment of Valtrex^* (Valaciclovir, VACV) the l-valyl Ester of Acyclovir (ACV).
pp. 342-342(1)
Authors: Szczech G.; de Miranda P.

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in HIV-Infected Persons.
pp. 343-343(1)
Author: Lalezari J.P.

Sorivudine (BV-ara-U) for the treatment of complicated refractory varicella zoster virus infection in HIV-infected patients.
pp. 343-343(1)
Authors: Burdge D.; Voigt R.; Gage L.; Lindley J.; Sacks S.

Famciclovir: Effect on Pain in Herpes Zoster
pp. 344-344(1)
Authors: Dworkin R.H.; Boon R.J.; Griffin D.R.J.

Covariates in Herpes Zoster and Interpretation of Clinical Trial Data.
pp. 344-344(1)
Authors: Dworkin R.H.; Boon R.J.; Griffin D.R.J.

WIN 63843, A Metabolically Stable Broad Spectrum Antipicornaviral Compound.
pp. 345-345(1)
Authors: Diana G.D.; Rudewicz P.; Pevear D.C.; Nitz T.J.; Aldous D.J.; Robinson D.T.; Dutko F.J.; Aldi C.; Reuman M.; Bailey T.R.; Czerniak R.; Block T.; Roland R.

Antipicornavirus Activity of SCH 47802: In Vitro and In Vivo Studies.
pp. 345-345(1)
Authors: Cox S.; Buontempo P.; Wright-Minogue J.; Skelton A.; DeMartino J.; Rozhon E.; Linn C.; Girijavallablan V.; Schwartz J.; O'Connell J.

Mechanism of Action of SCH 47802, an Antipicornavirus Molecule.
pp. 346-346(1)
Authors: Buontempo P.; Wright-Minogue J.; Cox S.; DeMartino J.; Girijavallablan V.; Rozhon E.; Schwartz J.; O'Connell J.

Anti-Picornavirus Activity of New Substituted Flavons and Flavanones
pp. 346-346(1)
Authors: Tomao P.; Conti C.; Orsi N.; Desideri N.; Sestili I.; Stein M.L.

Effects of the Nucleoside-Analogue Antiviral Agent Ribavirin in Persistently Coxsackie-virus B3 Infected Human Myocardial Fibroblasts
pp. 347-347(1)
Authors: Heim A.; Drescher J.; Stille-Siegener M.; Brehm C.; Grumbach I.; Figulla H.R.

Aporphinoid Alkaloid Glaucinone: A Selective Inhibitor of Poliovirus Replication
pp. 347-347(1)
Authors: Galabov A.S.; Nikolaeva L.; Philipov S.

Rapid In Vivo Development of Influenza A (H3N2) Virus Resistance to Amantadine and Rimantadine.
pp. 348-348(1)
Authors: Sidwell R.W.; Bailey K.W.; Wong M.H.; Morrison A.G.; Huffman J.H.

Inhibitory Effect of a Series of Protease Inhibitors on Influenza Virus Replication In Vitro.
pp. 348-348(1)
Authors: Hosoya M.; Kawamura H.; Ishii T.; Suzuki H.; Watanabe J.; Shigeta S.

Evaluation of aerosolized aprotinin therapy for influenza and parainfluenza infections in humans
pp. 349-349(1)
Authors: Ovcharenko A.V.; Kirzhner L.S.; Malyshev N.A.; Zhirnov O.P.

Anti-respiratory Syncytial Virus Activity of Selected Polyoxometalates.
pp. 349-349(1)
Authors: Barnard D.L.; Hill C.L.; Gage T.L.; Sidwell R.W.; Schinazi R.F.

Antiviral effect of coumarin analogue against respiratory syncytical virus infection in vitro and in vivo
pp. 350-350(1)
Authors: Yang Z.; Xiao H.; Liu Y.; Liu J.; Wen L.

Synthetic Peptides from Conserved Regions of Respiratory Syncytial Virus Fusion (F) Protein are Potent Inhibitors of Viral Fusion.
pp. 350-350(1)
Authors: Lambert A.L.; Barney S.; Guthrie K.; Medinas R.; Davis-Rhodes D.E.; Bucy T.; Erickson J.; Merutka G.; Petteway S.R.; Lambert D.M.

Comparative Inhibitory Effects of Ribavirin, Pyrazofurin, and EICAR on Measles (SSPE) Virus Replication In Vitro and In Vivo.
pp. 351-351(1)
Authors: Hosoya M.; Honda Y.; Ishii T.; Suzuki H.; Mori S.; Shigeta S.

An Antiviral Synthetic Coiled-Coil Peptide Displays Sustained Blood Levels in Rats.
pp. 351-351(1)
Authors: Lambert D.M.; Venetta T.; DiMassimo E.I.; Matthews J.; Petteway S.R.

Synthetic Peptides from Conserved Regions of Measles Virus Fusion Proteins are Potent Inhibitors of Viral Fusion.
pp. 352-352(1)
Authors: Guthrie K.; Barney S.; Davis-Rhodes D.E.; Lambert A.L.; Medinas R.; Bucy T.; Erickson J.; Merutka G.; Petteway S.R.; Lambert D.M.

Synthetic Peptides from Conserved Regions of Human Parainfluenza Type 3 Virus Fusion Protein are Potent Inhibitors of Viral Fusion.
pp. 352-352(1)
Authors: Barney S.; Lambert A.L.; Guthrie K.; Medinas R.; Davis-Rhodes D.E.; Bucy T.; Erickson J.; Merutka G.; Petteway S.R.; Lambert D.M.

Plant polysaccharide antiviral agents from Astragalus and Sterculia species.
pp. 353-353(1)
Authors: Smee D.F.; Verbiscar A.J.

Drug interactions with mopyridone
pp. 353-353(1)
Authors: Tantcheva L.; Rangelova D.

Effect of Topical Corticosteroids on the Antiviral Inhibitory Activity of Topical (S)-HPMPC in the AD5/NZ Rabbit Ocular Model.
pp. 354-354(1)
Authors: Gordon Y.; Romanowski E.; Araullo-Cruz T.

Inducibility of squamous differentiation by interferons determines antigen presentation in HPV negative and positive keratinocytes in vivo and in vitro.
pp. 354-354(1)
Authors: Tyring S.K.; Arany I.; Brysk M.M.

Squamous differentiation in HPV negative and positive keratinocytes determines the extent of interferon-induced growth arrest.
pp. 355-355(1)
Authors: Arany I.; Brysk M.M.; Brysk H.; Tyring S.K.

Antiviral Effect on Infectious Pancreatic Necrosis Virus Replication
pp. 355-355(1)
Authors: Jashes M.; Sandino A.M.; De Clercq E.

Highly Selective Inhibitors of Terminal Deoxynucleotidyl Transferase in Cell Free Systems
pp. 356-356(1)
Authors: Krayevsky A.A.; Dyatkina N.B.; Semizarov D.G.; von Janta-Lipinski M.

Effects of inhibitors of intracellular transport on the replication of Junin virus.
pp. 356-356(1)
Authors: Damonte E.B.; Candurra N.A.

Haemorrhagic fever with renal syndrome (Korean haemorrhagic fever in Korea) a challenge in diagnosis & treatment: report of 10 cases with atypical presentation
pp. 357-357(1)
Authors: Huggins J.; Lofts R.; Rossi C.; Arthur J.; Smith J.; Korch G.; Choi B.; Yi S.; Petzold R.

Modulation of antiviral immune responses by exogenous cytokines effects of TNF-,, interleukin-1, interleukin-2 on the immunogenicity of an inactivated tick-born encephalitis vaccine.
pp. 357-357(1)
Authors: Kashentseva E.A.; Ignatyev G.M.; Leskov V.P.; Kusliy A.G.

Inhibition of HIV-1 Infection of Macrophages and H9 Cells by Free or Liposome-Encapsulated L-689,502, an Inhibitor of the Viral Protease
pp. 358-358(1)
Authors: Pretzer E.; Flasher D.; Duzgunes N.

The Cyclic Congener of Cidofovir has Reduced Nephrotoxicity in Three Species.
pp. 358-358(1)
Authors: Hitchcock M.J.M.; Lacy S.A.; Lindsey J.R.; Kern E.R.

Therapeutic Effect of L-HSA-AraAMP on Serum DHBV-DNA in DHBV Infected Duckling.
pp. 359-359(1)
Authors: Yang H.-w.; Zhang L.-x.; Liu D.-p.; Wang H.-f.; Shao S.

Antiviral Activity of CH₃₁ Against HHV-6 in Vitro.
pp. 359-359(1)
Authors: Yang H.-w.; Zhang X.-q.; Liu D.-p.; shao S.